VI Autologous Bone Marrow Transplantation.pdf - Blog Science ...

transplantation for refractory solid tumors. Cancer Res 49:4654-4658,1989.
15. McKenzie R, Alberts D, Bishop M, et al: Phase I trail of high dose cyclophosphamide,
mitoxantrone and carboplatin with autologous bone marrow transplantation in
female malignancies: Pharmacologic levels of mitoxantrone and high response rate
in refractory ovarian cancer. Proceed ASCO 10:186,1991.
16. Legros M, Fleury J, Cure P, et al: High-dose chemotherapy and autologous bone
marrow transplant in 31 advanced ovarian cancers: Long term results. Proceed
ASCO 11:222,1992.
Table 1
Clinical characteristics of U.S. ovarian cancer ABMT patients
—Centers or studies surveyed 11
—Total number of patients 153
—Number (%) with relapsed/refractory disease 146(95%)
—Number transplanted in first remission 7 (5%)
—Median number (range) of prior regimens 2(1-3)
—Number of ABMT preparative regimens 20
—Median number (range) of patients/regimen 7 (1-20)
Table 2
Clinical results of ABMT for relapsed/refractory ovarian
cancer: Survey of U.S. programs
—Number of patients 146
—Number (%) early deaths 16 (10.5%)
—Number (%) évaluable for response* 82 (56%)
—Number (%) responding* 58 (71%)
—Number (%) entering a CR 35 (43%)
—Number (%) platinum sensitive 37/98 (38%)
—%CR+PR/CR with platinum sensitive disease 87%/73%
—% CR+PR/CR with platinum resistant disease 85%/34%
—Median time (months; range) to progression 6(3-12)
—% disease-free at 1 year 14%
*Patients with measurable disease who have a PR or CR
SIXTH INTERNATIONAL SYMPOSIUM ON AUTOLOGOUS BONE MARROW TRANSPLANTATION 197